Table 1.

Gene testing tools used for HR+ breast cancer

Gene Testing Tool	Number of Genes	Clinical Application	Involved Clinical Trials	References
Oncotype DX	21	Predicts 10-year recurrence risk in ER+ and LN- patients	In the NSABP B-14 trial, patients receiving endocrine therapy showed 10-year distant recurrence rates of 6.8%, 14.3%, and 30.5% in the low, intermediate, and high-risk groups, respectively (P < 0.001).	[61]
Prosigna	55	Predicts prognosis in postmenopausal women with Stage I or II ER+ and LN+/- breast cancer	In the ABCSG-8 trial, the ROR score significantly enhanced prognostic information beyond clinical predictors (P < 0.0001). Luminal A subtype showed a significantly lower 10-year ROR compared to Luminal B (P < 0.0001).	[62]
MammaPrint	70	Predicts distant recurrence risk in Stage I or II ER+/- and LN- patients	MammaPrint demonstrated the strongest prognostic ability for distant metastasis-free survival (dMFS) within the first 5 years after cancer diagnosis (HR=9.6; 95% CI: 4.2-22.1).	[63]
EndoPredict	11	Predicts 10-year recurrence risk in women with ER+ and LN+/- disease receiving endocrine therapy only	In the ABCSG-6 cohort, the 10-year distant recurrence rates were 8% (3%-13%) in the EP low-risk group and 22% (15%-29%) in the high-risk group (P < 0.001); in ABCSG-8, these rates were 6% (2%-9%) and 15% (11%-20%) in the low- and high-risk groups, respectively (P < 0.001).	[64]